SCHEDULE: Janus Henderson Boosts Mereo BioPharma Stake to 10.2%

Janus Henderson Group plc and its affiliates have reported an increased beneficial ownership of 10.2% in Mereo BioPharma Group PLC's American Depositary Shares.

Summary

• Janus Henderson Group plc, along with its affiliates, has filed an Amendment No. 6 to Schedule 13G regarding its beneficial ownership in Mereo BioPharma Group PLC.
• As of September 30, 2025, Janus Henderson Group plc beneficially owns 16,290,130 American Depositary Shares (ADS) of Mereo BioPharma Group PLC.
• This represents 10.2% of the class of securities.
• Janus Henderson Biotech Innovation Master Fund Ltd, an affiliate, beneficially owns 13,759,885 ADS, representing 8.7% of the class.
• The securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: A significant and sustained institutional ownership stake by a reputable investment firm like Janus Henderson Group plc, particularly through a biotech-focused fund, generally signals a positive view on the company's long-term prospects and stability. The filing is an amendment, suggesting an ongoing position rather than a new entry or exit.

Positives

• A significant institutional investor, Janus Henderson Group plc, maintains a substantial 10.2% stake in Mereo BioPharma Group PLC, indicating continued confidence in the company.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment strategy rather than an activist position.

Future Outlook

The filing does not provide any forward-looking statements or guidance from Mereo BioPharma Group PLC or Janus Henderson Group plc regarding the issuer's future performance.

Industry Context

The continued significant stake by a major investment manager like Janus Henderson, particularly its Biotech Innovation Master Fund, suggests ongoing interest in the biopharmaceutical sector and Mereo BioPharma's specific position within it. This indicates that Mereo BioPharma remains a relevant player for institutional investors focused on biotech.

Stakeholder Impact

• Shareholders: The continued significant institutional ownership by Janus Henderson may instill confidence among other shareholders and potentially attract new investors, as it signals a professional endorsement of Mereo BioPharma's value.
• Management: The stable institutional backing could provide management with greater stability and support for their strategic initiatives.

Key Dates

Recommendation

The filing indicates a significant, stable institutional ownership by Janus Henderson, a reputable investment firm. This suggests a positive long-term view from a major player. While it doesn't provide new operational or financial data to warrant a 'buy' or 'sell' action, the sustained institutional confidence supports a 'hold' recommendation for existing investors, implying that the investment thesis remains intact from a major institutional perspective.

Keywords

Mereo BioPharma Group PLC, Janus Henderson Group plc, Schedule 13G, Beneficial Ownership, American Depositary Shares, Biopharma, Institutional Investment, Equity Stake